Try our beta test site
23 studies found for:    Open Studies | diffuse large b-cell lymphoma OR DLBCL AND CNS | Phase 3
Show Display Options
Rank Status Study
1 Recruiting CNS Prophylaxis in Diffuse Large B-cell Lymphoma
Intervention: Drug: Methotrexate
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Study Start: July 2015
2 Recruiting Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
Interventions: Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: May 2016
3 Recruiting Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
Interventions: Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: October 2015
4 Recruiting The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
Interventions: Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: October 2015
5 Recruiting Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Interventions: Biological: Avelumab;   Biological: Utomilumab;   Biological: Rituximab;   Other: Azacitidine;   Drug: Bendamustine;   Drug: Gemcitabine;   Drug: Oxaliplatin
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Study Start: December 16, 2016
6 Recruiting MabionCD20® Compared to MabThera® in Lymphoma Patients
Interventions: Drug: Rituximab;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: prednisone
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator);   Primary Purpose: Treatment
Study Start: December 2015
7 Recruiting Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
Interventions: Drug: Lenalidomide;   Drug: Rituximab
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Study Start: August 2014
8 Recruiting High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Interventions: Drug: Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);   Drug: Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: July 2014
9 Recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Interventions: Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Crossover Assignment;   Masking: Participant, Care Provider, Investigator;   Primary Purpose: Treatment
Study Start: July 2016
10 Recruiting Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Interventions: Drug: R-DHAP;   Drug: BR-DHAP
Phases: Phase 2 / Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: February 2013
11 Recruiting A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions: Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
Phases: Phase 2 / Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Study Start: June 2016
12 Recruiting Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma
Interventions: Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202
Phases: Phase 2 / Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Study Start: June 2016
13 Recruiting Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma
Interventions: Drug: lenalidomide;   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: prednisone;   Drug: vincristine
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant, Care Provider, Investigator, Outcomes Assessor;   Primary Purpose: Treatment
Study Start: January 21, 2015
14 Recruiting R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Interventions: Drug: R-DA-EPOCH-21;   Drug: R-DA-EPOCH-21 + auto-SCT;   Drug: R-mNHL-BFM-90;   Drug: R-mNHL-BFM-90 + auto-SCT
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: February 2015
15 Not yet recruiting A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
Interventions: Drug: SCT400 plus CHOP;   Drug: Rituximab plus CHOP
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Single Blind (Subject);   Primary Purpose: Treatment
Study Start: June 2016
16 Recruiting R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
Interventions: Drug: Pegylated liposomal doxorubicin;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Cyclophophamide;   Drug: Vincristine;   Drug: Prednisone
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: September 2015
17 Not yet recruiting A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
Interventions: Drug: IBI301 plus CHOP;   Drug: Rituximab plus CHOP
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Study Start: August 2016
18 Recruiting Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.
Interventions: Radiation: Standard Arm;   Radiation: Experimental Arm
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Participant;   Primary Purpose: Treatment
Study Start: November 2016
19 Recruiting Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
Interventions: Drug: vindesine;   Drug: cyclophosphamide;   Drug: Epirubicin;   Drug: prednisone tablets;   Drug: Cinobufacini Tablets;   Drug: Rituximab
Phases: Phase 2 / Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: No masking;   Primary Purpose: Treatment
Study Start: September 2016
20 Not yet recruiting Thalidomide Maintenance Treatment in DLBCL
Interventions: Drug: Thalidomide;   Other: Observation
Phase: Phase 3
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Study Start: February 2017

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.